Europe Active Pharmaceutical Ingredients (API) 麻豆原创 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0221039

Publication Date:

February 26, 2021

Pages:

167

Publisher:

Grace 麻豆原创 Data

Countries:

Europe [1]

USD 2,480.00

Research & Development (Pharma & Healthcare) [2]

Pharmaceutical Manufacturing [3]

IT & eHealth [4]

Pharma & Healthcare [5]

Description:

Europe active pharmaceutical ingredients (API) market accounted for $45.77 billion in 2020 and will grow by 7.5% annually over 2020-2027 the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
Highlighted with 100 tables and 69 figures, this 167-page report 鈥淓urope Active Pharmaceutical Ingredients (API) 麻豆原创 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Europe API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2020 and provides forecast from 2021 till 2027 with 2020 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
Synthetic API
鈥� Branded Synthetic API
鈥� Generic Synthetic API
Biotech API by Drug Type:
鈥� Monoclonal Antibodies
鈥� Recombinant Proteins
鈥� Vaccines
鈥� Other Biotech APIs
Biotech API by Customer Base:
鈥� Innovative Biologic API
鈥� Generic Biosimilar API
Biotech API by Expression Technology:
鈥� Mammalian Expression
鈥� Microbial Expression
鈥� Yeast Expression
鈥� Insect Expression
鈥� Other Expression Technologies
HPAPI
鈥� Branded HPAPI
鈥� Generic HPAPI

Based on Manufacturing Process, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
Captive Manufacturing
鈥� Branded Captive API
鈥� Generic Captive API
Merchant Manufacturing by Drug Type:
鈥� Branded Merchant API
鈥� Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
鈥� Merchant Synthetic API
鈥� Merchant Biotech API

Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Ophthalmology
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Pulmonary Disorders
鈥� Orthopedics
鈥� Other Applications

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
鈥� Branded Prescription Drugs
鈥� Generic Prescription Drugs
鈥� OTC Drugs

Geographically, the following national/local markets are fully investigated:
鈥� Germany
鈥� UK
鈥� France
鈥� Spain
鈥� Italy
鈥� Russia
鈥� Rest of Europe (further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue are available for 2017-2027. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe API market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of 麻豆原创 Research Methodology 13
1.2.2 麻豆原创 Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 16
1.2.6 麻豆原创 Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 麻豆原创 Overview and Dynamics 21
2.1 麻豆原创 Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the 麻豆原创 25
2.2 Major Growth Drivers 27
2.3 麻豆原创 Restraints and Challenges 32
2.4 Emerging Opportunities and 麻豆原创 Trends 35
2.5 Porter鈥檚 Fiver Forces Analysis 39
3 Segmentation of Europe 麻豆原创 by Synthesis 43
3.1 麻豆原创 Overview by Synthesis 43
3.2 Synthetic API 45
3.2.1 Branded Synthetic API 46
3.2.2 Generic Synthetic API 47
3.3 Biotech API 48
3.3.1 Biotech API by Drug Type 49
3.3.1.1 Monoclonal Antibodies 50
3.3.1.2 Recombinant Proteins 51
3.3.1.3 Vaccines 52
3.3.1.4 Other Biotech APIs 53
3.3.2 Biotech API by Customer Base 54
3.3.2.1 Innovative Biologic API 55
3.3.2.2 Generic Biosimilar API 56
3.3.3 Biotech API by Expression Technology 57
3.3.3.1 Mammalian Expression 58
3.3.3.2 Microbial Expression 59
3.3.3.3 Yeast Expression 60
3.3.3.4 Insect Expression 61
3.3.3.5 Other Expression Technologies 62
3.4 HPAPI 63
3.4.1 Branded HPAPI 64
3.4.2 Generic HPAPI 65
4 Segmentation of Europe 麻豆原创 by Manufacturing Process 66
4.1 麻豆原创 Overview by Manufacturing Process 66
4.2 Captive Manufacturing 68
4.2.1 Branded Captive API 69
4.2.2 Generic Captive API 70
4.3 Merchant Manufacturing 71
4.3.1 Merchant Manufacturing by Drug Type 72
4.3.1.1 Branded Merchant API 73
4.3.1.2 Generic Merchant API 74
4.3.2 Merchant Manufacturing by Drug Synthesis 75
4.3.2.1 Merchant Synthetic API 76
4.3.2.2 Merchant Biotech API 77
5 Segmentation of Europe 麻豆原创 by Therapeutic Application 78
5.1 麻豆原创 Overview by Therapeutic Application 78
5.2 Infectious Diseases 80
5.3 Oncology 81
5.4 Ophthalmology 82
5.5 Cardiovascular Disorders 83
5.6 Central Nervous System 84
5.7 Pulmonary Disorders 85
5.8 Orthopedics 86
5.9 Other Applications 87
6 Segmentation of Europe 麻豆原创 by Drug Type 88
6.1 麻豆原创 Overview by Drug Type 88
6.2 Branded Prescription Drugs 90
6.3 Generic Prescription Drugs 91
6.4 OTC Drugs 92
7 European 麻豆原创 2020-2027 by Country 93
7.1 Overview of European 麻豆原创 93
7.2 UK 96
7.3 France 98
7.4 Germany 100
7.5 Spain 102
7.6 Italy 104
7.7 Russia 106
7.8 Rest of European 麻豆原创 108
8 Competitive Landscape 110
8.1 Overview of Key Vendors 110
8.2 New Product Launch, Partnership, Investment, and M&A 113
8.3 Company Profiles 114
AbbVie Inc. 114
Astrazeneca 116
Aurobindo Pharma Ltd. 119
BASF 121
Bayer AG 124
Boehringer Ingelheim 126
Dr. Reddy's Laboratories 130
F. Hoffmann-La Roche 132
GlaxoSmithKline plc 134
Lonza Group 138
Lupin Limited 142
Merck & Co., Inc. 144
Mylan NV 146
Novartis International AG 148
Pfizer Inc. 150
Sanofi 154
Sun Pharmaceutical Industries Ltd. 156
Teva Pharmaceutical Industries Ltd. 158
9 Investing in Europe 麻豆原创: Risk Assessment and Management 161
9.1 Risk Evaluation of Europe 麻豆原创 161
9.2 Critical Success Factors (CSFs) 164
Related Reports and Products 167

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.